AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest
Swedish Biotech Is Developing Broad CNS portfolio
Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.
You may also be interested in...
While a so-called disease modifying treatment has entered the market for the first time, in the form of Biogen’s Aduhelm, Alzheimer’s disease is unlikely to be cured by one drug alone. In Vivo explores the array of approaches to AD drug development, drawing on interviews with industry leaders and pipeline data.
Biogen/Eisai’s Alzheimer’s drug aducanumab could face difficulties with health technology appraisal institutes should it win approval in the EU.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.